Article info
PDFHow to understand it
Using biomarkers to predict clinical outcomes in multiple sclerosis
- Correspondence to DrEmma CTallantyre, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff CF10 3AT, UK; tallantyreec{at}cardiff.ac.uk
Citation
Using biomarkers to predict clinical outcomes in multiple sclerosis
Publication history
- Accepted March 25, 2019
- First published June 26, 2019.
Online issue publication
June 23, 2020
Article Versions
- Previous version (23 June 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Antibodies to neurofilament light as potential biomarkers in multiple sclerosis
- Prognostication and contemporary management of clinically isolated syndrome
- Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude
- Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients
- Neurofilament light chain as a biomarker in neurological disorders
- Voxel-wise mapping of cervical cord damage in multiple sclerosis patients with different clinical phenotypes
- Role of genetic susceptibility variants in predicting clinical course in multiple sclerosis: a cohort study
- Association of serum neurofilament light with microglial activation in multiple sclerosis
- Cerebrospinal fluid anti-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosis
- Genetically determined serum serine level has a novel causal effect on multiple sclerosis risk and predicts disability progression